Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EPS (Weighted Average and Diluted) (2022 - 2025)

Bioregenx's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.0 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.0 for Q4 2025, up 94.7% from a year ago — trailing twelve months through Dec 2025 was -$0.0 (up 91.96% YoY), and the annual figure for FY2025 was -$0.0, up 94.64%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.0 at Bioregenx, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.0 in Q2 2023 to a low of -$0.02 in Q4 2024.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.0 (2025), against an average of -$0.0.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 95.61% in 2023, then tumbled 21246.47% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then plummeted by 5384.25% to -$0.0 in 2023, then plummeted by 1677.25% to -$0.02 in 2024, then skyrocketed by 94.7% to -$0.0 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.0, -$0.0, and -$0.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.